Alka-Seltzer Heartburn and Pain
NDC 0280-0160, ANHYDROUS CITRIC ACID, ASPIRIN, and SODIUM BICARBONATE, tablet, effervescent, from Bayer HealthCare LLC..
- Product NDC
- 0280-0160
- Status
- Listed
- Labeler
- Bayer HealthCare LLC.
- Dosage form
- TABLET, EFFERVESCENT
- Route
- ORAL
- Product type
- HUMAN OTC DRUG
- Marketing category
- OTC MONOGRAPH DRUG
- Application
- M013
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/0280-0160 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- ANHYDROUS CITRIC ACID1000 mg/1
- ASPIRIN325 mg/1
- SODIUM BICARBONATE1916 mg/1
Pharmacologic classes
Acidifying Activity [MoA]; Alkalinizing Activity [MoA]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Anti-coagulant [EPC]; Calcium Chelating Activity [MoA]; Calculi Dissolution Agent [EPC]; Cyclooxygenase Inhibitors [MoA]; Decreased Coagulation Factor Activity [PE]; Decreased Platelet Aggregation [PE]; Decreased Prostaglandin Production [PE]; Nonsteroidal Anti-inflammatory Drug [EPC]; Platelet Aggregation Inhibitor [EPC]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 0280-0160-01 | 00280016001 | 58 POUCH in 1 CARTON (0280-0160-01) / 2 TABLET, EFFERVESCENT in 1 POUCH |
| 0280-0160-02 | 00280016002 | 6 POUCH in 1 CARTON (0280-0160-02) / 2 TABLET, EFFERVESCENT in 1 POUCH |
| 0280-0160-03 | 00280016003 | 12 POUCH in 1 CARTON (0280-0160-03) / 2 TABLET, EFFERVESCENT in 1 POUCH |
| 0280-0160-04 | 00280016004 | 18 POUCH in 1 CARTON (0280-0160-04) / 2 TABLET, EFFERVESCENT in 1 POUCH |
| 0280-0160-05 | 00280016005 | 36 POUCH in 1 CARTON (0280-0160-05) / 2 TABLET, EFFERVESCENT in 1 POUCH |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.
Use it
Look up 0280-0160 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/0280-0160 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 0280-0160. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.